Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 176,900 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 176,900 shares of the stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00. Following the sale, the chief operating officer now directly owns 668,680 shares in the company, valued at $7,903,797.60. This trade represents a 20.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Eric Venker also recently made the following trade(s):

• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total transaction of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Price Performance

Shares of ROIV opened at $12.08 on Friday. Roivant Sciences Ltd. has a 1 year low of $9.69 and a 1 year high of $13.06. The stock has a 50 day simple moving average of $11.92 and a two-hundred day simple moving average of $11.56. The firm has a market cap of $8.79 billion, a P/E ratio of 2.14 and a beta of 1.25.

Analyst Ratings Changes

ROIV has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, Bank of America upped their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.93.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently made changes to their positions in ROIV. Clearbridge Investments LLC lifted its stake in Roivant Sciences by 51.3% in the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock worth $19,666,000 after purchasing an additional 630,712 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of Roivant Sciences by 40.1% in the second quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock worth $6,840,000 after buying an additional 185,226 shares during the period. Exchange Traded Concepts LLC bought a new stake in shares of Roivant Sciences in the 3rd quarter valued at about $2,267,000. TOMS Capital Investment Management LP purchased a new stake in Roivant Sciences during the 3rd quarter valued at about $46,333,000. Finally, Barclays PLC grew its position in Roivant Sciences by 19.7% during the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock worth $5,302,000 after acquiring an additional 75,609 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.